IM Cannabis Corp. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how IM Cannabis Corp. performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do and how did they perform?

IM Cannabis supplies medical cannabis in Israel and Germany, managing the entire process from cultivation to retail. For the year ending December 31, 2023, the company generated approximately $35.4 million CAD in revenue. This year, the company focused on streamlining operations by closing inactive branches and acquiring 100% ownership of their key subsidiary, Focus Medical Herbs Ltd., allowing them to retain all future profits from that entity.

2. Financial performance

The company reported a loss of approximately $23.5 million CAD for the year. This figure includes a $1 million CAD "impairment loss" on their German licenses, reflecting a downward adjustment in the valuation of those assets. Additionally, the company pays roughly $526k CAD in annual management fees to entities controlled by their own shareholders, while daily operating costs continue to exceed profit margins.

3. Major wins and challenges

• The Win: Moving from 74% to 100% ownership of Focus simplifies the corporate structure and eliminates the need to share profits with minority partners.
• The Challenge: Cash flow is tight. The company currently operates with a working capital deficit, meaning they struggle to cover short-term obligations. They are utilizing unpaid customer invoices as collateral for loans, which indicates a reliance on borrowing against future income to fund current daily operations.

4. Financial health and recent updates

The company maintains its operations by selling private shares and securing loans that can be converted into equity. They also carry significant long-term debt that requires regular interest payments. Since the end of the fiscal year, they have secured a $1.5 million USD bridge loan from their own leadership. While this provides immediate liquidity, these types of arrangements often lead to the issuance of more shares, which can reduce your ownership percentage and dilute the value of your current holdings.

5. Key risks

• Shareholder Ties: The company maintains consulting and loan agreements with entities controlled by its own Chairman and CEO. These arrangements create potential conflicts of interest regarding whether these deals are structured for the company’s benefit or for the convenience of insiders.
• Liquidity: The reliance on short-term loans leaves the company with very little financial flexibility. If customer payments are delayed or market regulations shift, the company may face a cash crisis, potentially forcing them to issue more shares to survive.

6. Competitive positioning

The company is currently in a "survival" phase rather than a "growth" phase. The write-down of their German assets highlights the difficulty they have faced in establishing a foothold in that market. With high production costs and stiff competition in Israel, the company’s future depends on their ability to increase sales while aggressively cutting the overhead costs that currently consume their cash reserves.

---

Final Thought for Investors: When considering this company, weigh the potential of their simplified business structure against the risks of their current cash crunch and the ongoing reliance on insider-led financing. If you are looking for a stable, cash-flow-positive investment, the current "survival" mode of this company may require a higher risk tolerance than a more established competitor.